Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anorexia Nervosa
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Juvenile Idiopathic Arthritis
Interventions: CNTO 148 (Golimumab), Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more

Conditions: Psoriasis
Interventions: Daclizumab, NB-UVB; Drug · Device
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 3
States / cities: New York, New York

Conditions: Psoriasis
Interventions: peficitinib, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more

Conditions: ADHD
Interventions: OROS methylphenidate; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 6 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Placebo Effect
Interventions: Caffeine Anhydrous with small sucrose pill, Placebo - large sucrose pill, Caffeine Anhydrous with large sucrose pill, Placebo - small sucrose pill; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Schizophrenia
Interventions: TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cluster Headache
Interventions: 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin (0.25mg/kg), Niacin (250mg); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions: Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents; Drug · Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 6 Years to 14 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New Hyde Park, New York • Stony Brook, New York

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions: Genistein, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: SARS-CoV-2, COVID-19
Interventions: Hydroxychloroquine, Azithromycin, Placebo oral tablet; Drug
Lead sponsor: Salomeh Keyhani MD; Federal
Eligibility: 216 Months and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Neutropenia
Interventions: F-627, Placebo; Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Diabetic Peripheral Neuropathy
Interventions: Tanezumab, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 48
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: PANCRECARB® (pancrelipase), Placebo; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Pegozafermin, Placebo; Biological · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 154
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more

Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more

Conditions: Healthy Volunteers
Interventions: RP7214, Placebo; Drug
Lead sponsor: Rhizen Pharmaceuticals SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Las Vegas, Nevada • Fargo, North Dakota

Search by objective public record fields.

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

The Effect of Tablet Size on Cognitive Performance Caffeine

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Psilocybin for the Treatment of Cluster Headache

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects